Pfizer announced Monday that it is to extend its strategic collaboration with Saama, via the signing of a new multi-year agreement in artificial intelligence.

The American biopharmaceutical group says this partnership follows a first successful cooperation, which started in 2020 to automate its data review processes using AI.

The project enabled Pfizer to improve the quality of its database management.

Pfizer now intends to use AI as part of its broader activities surrounding the conduct of clinical trials.

Pfizer recalls that Saama had already helped it, in 2020, to accelerate clinical studies for its Covid vaccine with the implementation of an AI-powered technology platform.

Copyright (c) 2024 CercleFinance.com. All rights reserved.